Using a da Vinci robot for breast cancer surgery? Is it safe? Effective?
After 45 years of covering oncology, we stopped and asked our readers: who are you?
Last week, I discussed events resulting in the Chernobyl NPF accident, including unique aspects of the reactor-design which contributed to the accident, and which resulted in release of radiation to the environment. I also discussed the initial Soviet response. Next, I focus on the immediate medical consequences and the response of Soviet government to medical interventions.
As a physician-scientist, I have spent my career advancing research in women's health. I was a part of the planning effort to design and launch TMIST—the Tomosynthesis Mammographic Imaging Screening Trial.
Two weeks ago, HBO began screening a five-part series on Monday nights on the Chernobyl nuclear power facility (NPF) accident, which occurred more than 30 years ago on April 26, 1986.
When NCI renewed the Comprehensive Cancer Center designation for Rutgers Cancer Institute of New Jersey, it also acknowledged that the institution's catchment area now covers the entire state of New Jersey, having expanded from roughly three counties around its home location of New Brunswick.
Over the past decade there has been much consternation about overdiagnosis, the detection of cancers that would not have been diagnosed without screening.
Overdiagnosis is defined as the diagnosis of an asymptomatic cancer that would not have become clinically evident during the person's lifetime in the absence of screening or similar activities, such as diagnostic imaging tests that reveal “incidentalomas.”
Janssen Pharmaceuticals said Balversa (erdafitinib) received accelerated approval from FDA for the treatment of adults with locally advanced or metastatic urothelial carcinoma which has susceptible fibroblast growth factor receptor 3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients' tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score ≥1%) determined by an FDA-approved test.
